Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Nuance Pharma Acquires Rights to Nasal Spray in $23.5 Million Deal

publication date: Mar 7, 2022

Shanghai Nuance Pharma acquired China rights to a nasal spray developed by Switzerland's Altamira Therapeutics in a $23.5 million agreement. Bentrio™ (AM-301) is a drug-free nasal spray that forms a protective gel layer on the nasal mucosa, protecting against airborne viruses and allergens. It may also be effective against SARS-CoV-2. Nuance will make an upfront payment of $1 million and pay Altamira up to $22.5 million in milestones. Eventually, Nuance will have the right to manufacture the product in China and pay royalties on sales. More details....

Stock Symbol: (NSDQ: CYTO)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.